Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
Volunteers
Health Professionals
What is the purpose of this trial?
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Anna Sowa, MD, MHS
- Aron Flagg, MD
- Asher Marks, MD
- Claudia Auerbach, APRN
- Daniel Prior, MD
- Juan Vasquez, MD
- Kaitlin Brown
- Kenneth B. Roberts, MD
- Lakshmanan Krishnamurti, MD
- Mary Jane Hogan, MD, MPH, FAAP
- Michaela Russell
- Michelle Foley, DO
- Nicholas Moore, MD
- Nitya Bakshi, MBBS, MS
- Prasanna Ananth, MD, MPH
- Rozalyn Levine Rodwin, MD, MHS
- Stephanie Massaro, MD, MPH
- Stephanie Prozora, MD
- Vidya Puthenpura, MD, MHS, FAAP
- Last Updated01/18/2026
- Study HIC#2000041522